Heyman Tomas J. — SEC insider filings

SEC reporting owner CIK 1814673. 23 insider filings on record with FilingPulse; latest filed 2026-09-28.

Transaction summary — filings shown

Covers all 23 filings on record, filed 2020-12-04 to 2026-09-28. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Akero Therapeutics, Inc. (AKRO)Director7—1 leg · 26,000 sh · $1,421,52912
EXELIXIS, INC. (EXEL)Director5—1 leg · 4,544 sh · $201,2545
OptiNose, Inc. (OPTN)Director6——10
Invivyd, Inc. (IVVD)Director2——2
Xilio Therapeutics, Inc. (XLO)Director2——2
Legend Biotech Corp (LEGN)Director1——1

Insider filings — Heyman Tomas J.

FiledFormIssuerReported transactionsSource
2026-09-284Legend Biotech Corp (LEGN)Grant/award (A): 20,986 @ $0EDGAR
2026-05-294EXELIXIS, INC. (EXEL)Grant/award (A): 8,367 @ $0EDGAR
2025-12-094Akero Therapeutics, Inc. (AKRO)Disposition to issuer (D): 9,398 · Disposition to issuer (D): 26,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 13,000 (derivative)EDGAR
2025-06-054Akero Therapeutics, Inc. (AKRO)Grant/award (A): 9,398 @ $0EDGAR
2025-05-304EXELIXIS, INC. (EXEL)Grant/award (A): 9,812 @ $0EDGAR
2025-05-224EXELIXIS, INC. (EXEL)Sale (S): 4,544 @ $44.29EDGAR
2025-05-214OptiNose, Inc. (OPTN)Disposition to issuer (D): 5,000 (derivative) · Disposition to issuer (D): 3,566 (derivative) · Disposition to issuer (D): 2,133 (derivative) · Disposition to issuer (D): 962 (derivative) · Disposition to issuer (D): 1,925 (derivative)EDGAR
2024-06-114Akero Therapeutics, Inc. (AKRO)Grant/award (A): 26,000 (derivative) @ $0EDGAR
2024-06-074OptiNose, Inc. (OPTN)Grant/award (A): 75,000 (derivative) @ $0EDGAR
2024-06-044EXELIXIS, INC. (EXEL)Grant/award (A): 18,838 @ $0EDGAR
2023-06-274Akero Therapeutics, Inc. (AKRO)Grant/award (A): 15,000 (derivative) @ $0EDGAR
2023-06-214Akero Therapeutics, Inc. (AKRO)Option exercise (M): 26,000 @ $25.04 · Sale (S): 26,000 @ $54.67 · Option exercise (M): 26,000 (derivative) @ $0EDGAR
2023-06-134Xilio Therapeutics, Inc. (XLO)Grant/award (A): 13,200 (derivative) @ $0EDGAR
2023-06-094OptiNose, Inc. (OPTN)Grant/award (A): 53,500 (derivative) @ $0EDGAR
2023-06-024EXELIXIS, INC. (EXEL)Grant/award (A): 18,176 @ $0 · Grant/award (A): 36,353 (derivative) @ $0EDGAR
2023-05-254Invivyd, Inc. (IVVD)Grant/award (A): 50,000 (derivative) @ $0EDGAR
2022-09-164Xilio Therapeutics, Inc. (XLO)Grant/award (A): 26,400 (derivative) @ $0EDGAR
2022-06-244Adagio Therapeutics, Inc. (ADGI)Grant/award (A): 75,000 (derivative) @ $0EDGAR
2022-06-094OptiNose, Inc. (OPTN)Grant/award (A): 32,000 (derivative) @ $0EDGAR
2022-06-034Akero Therapeutics, Inc. (AKRO)Grant/award (A): 15,000 (derivative) @ $0EDGAR
2021-06-104OptiNose, Inc. (OPTN)Grant/award (A): 14,439 (derivative) @ $0EDGAR
2021-06-034Akero Therapeutics, Inc. (AKRO)Grant/award (A): 13,000 (derivative) @ $0EDGAR
2020-12-044OptiNose, Inc. (OPTN)Grant/award (A): 28,879 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-12-02 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1814673 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs